Tengion soars on raising $34M in support of organ regeneration platform

July 2, 2013 by Arezu Sarvestani

Tengion Inc. raises $33.6 million from a pair of investors supporting its Neo-Kidney Augment and Neo-Urinary Conduit clinical programs.

Tengion logo

North Carolina regenerative medicine company Tengion (NSDQ:TNGN) raised $33.6 million in support of clinical studies of its leading programs, the Neo-Kidney Augment and Neo-Urinary Conduit programs. TNGN shares jumped 15.3% to 68¢ around 12:40 p.m. today, up from an opening price of 64¢.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp